NCT01435525|Completed
Nexium Capsules Helicobacter Pylori Specific Clinical Experience Investigation
Nexium Capsules Specific Clinical Experience Investigation Concerning Helicobacter Pylori Eradication
Loading search results
Nexium Capsules Specific Clinical Experience Investigation Concerning Helicobacter Pylori Eradication
Sponsor study identifier
observational
369
1 country
36
Study Start
September 2011
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
March 2014
Actual (reported)Study Completion
March 2014
Actual (reported)The purpose of this study is to confirm the safety profile / factors which impact safety and efficacy in patients given triple therapy for Helicobacter pylori eradication with Nexium + amoxicillin (AMPC) + clarithromycin (CAM), or Nexium + AMPC + metronidazole (MNZ) in usual post-marketing use.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
March 2014
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
September 2011
Date type not reportedThis date has not been verified as actual or estimated.
September 14, 2011
Actual (reported)September 16, 2011
Actual (reported)March 2014
Actual (reported)March 2014
Actual (reported)Number of Adverse Drug Reactions
Period from the start of triple therapy to assessment of eradication, an expected average of 3 months
Rate of H.Pylori eradication
Period from the start of triple therapy to assessment of eradication, an expected average of 3 months
Patients to whom triple therapy for H.pylori eradication to stomach is started after endoscopic treatment for gastric ulcer, duodenal ulcer, gastric MALT lymphoma, idiopathic thrombocytopenic purpura, or early gastric cancer as the approved indication of Nexium. Patients with H.pylori negative at the time when the triple therapy is started are excluded.
Research Site
Aichi, Japan
Research Site
Akita, Japan
Research Site
Chiba, Japan
Research Site
Ehime, Japan
Research Site
Fukuoka, Japan
Research Site
Fukushima, Japan
Research Site
Gifu, Japan
Research Site
Shigeru Yoshida, MD
AstraZeneca
369 participants (actual enrollment reported by the registry).
First Submitted
September 14, 2011
First Posted
September 16, 2011
Study Start
September 2011
Date type not reportedThis date has not been verified as actual or estimated.
Efficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Non-steroidal Anti-inflammatory Drug (NSAID)
Contact the study team to confirm eligibility.
Gunma, Japan
Research Site
Hiroshima, Japan
Research Site
Hokkaido, Japan
Research Site
Hyōgo, Japan
Research Site
Ibaraki, Japan
Research Site
Kagawa, Japan
Research Site
Kanagawa, Japan
Research Site
Kochi, Japan
Research Site
Kumamoto, Japan
Research Site
Kyoto, Japan
Research Site
Mie, Japan
Research Site
Miyagi, Japan
Research Site
Nagano, Japan
Research Site
Nagasaki, Japan
Research Site
Niigata, Japan
Research Site
Numakunai, Japan
Research Site
Okayama, Japan
Research Site
Okinawa, Japan
Research Site
Osaka, Japan
Research Site
Ōita, Japan
Research Site
Saitama, Japan
Research Site
Shiga, Japan
Research Site
Shimane, Japan
Research Site
Shizuoka, Japan
Research Site
Tokyo, Japan
Research Site
Toyama, Japan
Research Site
Wakayama, Japan
Research Site
Yamagata, Japan
Research Site
Yamanashi, Japan
Primary Completion
March 2014
Actual (reported)Study Completion
March 2014
Actual (reported)Last Updated
April 16, 2014
Record last verified: 2014-04
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: